IRDAI Warns Niva Bupa on FY25 Expense Limits and Bars New Branches for Six Months: A Sector-Wide Sweep, Nil Financial Impact

On August 20, after market close, Niva Bupa disclosed an order dated August 19 from the Insurance Regulatory and Development Authority of India. In the filing's words, IRDAI had "sought explanation from the Company on Expense of Management (EoM) limits for financial year 2024-25", and by the order "the Company has been warned for not complying with the applicable EoM limits for the FY 2024-25 and has directed not to open new place of business for a period of six months from the date of order."

The company states that it is in compliance with the EoM Regulations, 2024 for the full year ended March 31, 2026 and for the quarter ended June 30, 2026, and "is on track to ensure compliance" for FY27. The Regulation 30 annexure records the financial impact as nil. No monetary penalty is mentioned, and there is no restriction on writing new business, on existing branches, agents or digital channels.

Expense-of-management limits cap what an insurer may spend on commissions and operating costs as a share of premium. The 2024 regulations gave insurers a glide path; FY25 was the first full year under them. In the same week as the Niva Bupa order, IRDAI issued warnings with identical six-month branch restrictions to Edelweiss Life, Pramerica Life and ACKO General for FY25 EoM breaches, as reported by Business Standard on August 23. Read against that, the order is a regulator closing out FY25 cases across the industry, not a finding specific to Niva Bupa's controls.

Three weeks before the order, Niva Bupa reported Q1 FY27 profit after tax of ₹138 crore, up 93% year on year, on gross written premium of ₹2,150 crore, up 32%. Retail health grew 47%, taking retail market share to 11.1%. The claim settlement ratio was 95.6% and the combined insurance service ratio improved to 100.2% from 103.2% a year earlier. The same board meeting approved raising up to ₹500 crore through unsecured subordinated NCDs on private placement, in one or more tranches.

The stock is 10.5% below its July 31 high, but most of that decline came in the three weeks between the results and the order, not on the order itself. RSI at 29 marks the unit as oversold on the daily; the price sits below the 20- and 50-day averages and above the 200-day.